Keywords: Novartis, Zometa, Afinitor, Breast cancer

Novartis’ Zometa fails to meet Ph III primary endpoint in early breast cancer, stalling this indication; but Afinitor looks good

Article | 10 December 2010

Print This

Results from the second interim analysis of the Phase III AZURE (Adjuvant Zoledronic acid to redUce REcurrence) trial show that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in